FDA Doubts Deramiocel as Capricor Loses 65% in One Day
The market reaction captured attention, but the regulatory dispute matters more. Capricor argues that HOPE-3 showed statistically significant benefits in upper-limb function and cardiac performance. However, FDA reviewers concluded that HOPE-3 and HOPE-2 do not provide substantial evidence that deramiocel slows functional or cardiac decline in DMD.
Therefore, the dispute extends beyond one p-value. The FDA questions whether the endpoints, analytical methods and study population support reliable conclusions for the proposed indication.
Capricor Called HOPE-3 Positive, Why FDA Still Was Not Convinced
FDA standards require evidence from adequate and well-controlled investigations. Consequently, a positive result must also remain clinically meaningful, scientifically justified and robust across credible analyses.
The agency said HOPE-3 did not meet its pre-specified primary and secondary efficacy endpoints under the original analytical approach. Capricor reached a different conclusion after applying later versions of the statistical analysis plan. The company says it finalized SAP version 3.0 before database lock and unblinding and that the resulting analyses showed significant benefits.
However, the FDA does not accept statistical significance as sufficient proof when later analytical changes reduce confidence in how the result emerged.
Did Late Statistical Changes Weaken Capricor’s Deramiocel Evidence?
FDA reviewers said Capricor changed endpoint definitions, analytical methods and missing-data strategies after the double-blind study period ended. The agency also said Capricor did not submit the final SAP for review before the BLA submission.
Safety Risks and Possible Unblinding Deepen FDA Concerns
The FDA also raised the possibility of functional unblinding. Hypersensitivity reactions occurred in 42% of deramiocel-treated patients and 15% of placebo recipients. Therefore, investigators or participants may have inferred treatment assignment despite formal blinding.
In addition, reviewers identified hypersensitivity reactions, including anaphylaxis. Without convincing efficacy evidence, those risks carry greater weight. As a result, FDA reviewers view deramiocel’s benefit-risk profile as unfavorable, while Capricor argues that the therapy offers value in a severe disease with high unmet medical need.
The Deramiocel FDA Review Sends a Warning to Pharma Quality Teams
The advisory committee will consider whether HOPE-3 provides substantial evidence of effectiveness for deramiocel in DMD cardiomyopathy. Its recommendation will not bind the FDA, but it will inform the agency’s final review.
For QA, Regulatory Affairs and Clinical Quality teams, the case shows that data alone cannot defend a submission. Teams must also preserve the credibility of every endpoint, statistical decision and controlled change.
Zamann Pharma’s Quality Management System support helps pharmaceutical teams strengthen change control, documentation governance and risk-based quality oversight. Explore the service to build traceable, inspection-ready decisions before regulatory questions place critical evidence at risk.
Source: Endpoints.News.Com